NCT06555744

A Study of ZW191 in Participants With Solid Tumors

A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 145 (estimated)
• Sponsor: Zymeworks BC Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.

Detailed description

Part 1 of the study will evaluate the safety and tolerability of ZW191. Part 2 of the study will further evaluate safety and explore the potential anti-tumor activity of ZW191.

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	ZW191	Administered intravenously

Timeline

• Start date: 2024-10-30
• Primary completion: 2026-12-01
• Completion: 2027-01-01
• First posted: 2024-08-15
• Last updated: 2026-04-09

Locations

27 sites across 6 countries: United States, Australia, Japan, Singapore, South Korea, Spain

Regulatory

• FDA-regulated drug study